Weight Regain After GLP-1 Medications

One of the most clinically important and underappreciated aspects of GLP-1 treatment is what happens when it stops. The STEP-4 trial provided the most rigorous data on this question — and the results reframe how to think about GLP-1 as treatment for a chronic disease.

The STEP-4 Data

STEP-4 enrolled semaglutide 2.4mg patients who had lost weight over 20 weeks, then randomized them to continue semaglutide or switch to placebo for 48 additional weeks.

By 68 weeks (48 weeks after randomization), the placebo group had regained approximately 2/3 of their original loss — despite being enrolled in a clinical trial with active behavioral support. This is a clinical trial population with higher-than-average support and monitoring; real-world regain may be higher.

The Regain Timeline

Stop medication
        ↓
Week 1–2: Food noise returns; hunger increases
        ↓
Month 1–3: ~3–4% body weight regained (early phase)
        ↓
Month 3–6: Accelerated regain as appetite fully rebounds
        ↓
Month 6–12: Most regain occurs; ~2/3 of loss recovered
        ↓
Month 12–24: Regain plateaus near original weight or new set point

Why Regain Is Not Personal Failure

Obesity is a chronic disease. Treating it with medication and stopping when weight is lost is equivalent to treating hypertension with medication until blood pressure normalizes, then stopping — and being surprised when it rises again.

Strategies to Reduce Regain After Stopping

If discontinuation is necessary (cost, side effects, pregnancy planning, elective break):

The maintenance dose option: Some providers transition patients to a lower dose (e.g., Wegovy 1.7mg instead of 2.4mg) rather than full discontinuation. This reduces cost while retaining partial appetite suppression — a middle path between full treatment and full stop.

When Regain Happens: Restarting

Restarting GLP-1 after regain follows the same protocol as initial treatment:

• Begin at the lowest dose (0.25mg/week semaglutide or 2.5mg/week tirzepatide)
• Step up per the standard titration schedule — stomach tolerance resets after stopping
• Weight loss response typically resumes — the underlying biology is the same

Clinical experience suggests re-responders to GLP-1 after stopping and restarting generally achieve similar weight loss to their first course of treatment. There is no evidence of tolerance or tachyphylaxis to GLP-1 medications with repeat use.

Related Resources

• GLP-1 Stopping FAQ — deciding whether to stop, discontinuation considerations
• GLP-1 Maintenance Dose FAQ — staying on lower doses long-term
• GLP-1 Obesity Disease FAQ — why obesity requires ongoing treatment
• GLP-1 Cost Effectiveness FAQ — long-term treatment cost analysis